Brexanolone
- PMID: 31643374
- Bookshelf ID: NBK548043
Brexanolone
Excerpt
Brexanolone is a unique, intravenously administered, neuroactive steroidal antidepressant used in the therapy of moderate-to-severe postpartum depression. In prelicensure clinical trials, brexanolone therapy was not associated with an increased rate of serum aminotransferase elevations, and it has not been linked to instances of clinically apparent acute liver injury.
Similar articles
-
Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.J Pharm Pract. 2022 Jun;35(3):431-436. doi: 10.1177/0897190020979627. Epub 2020 Dec 11. J Pharm Pract. 2022. PMID: 33302791 Review.
-
Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.Pharmacotherapy. 2019 Nov;39(11):1105-1112. doi: 10.1002/phar.2331. Epub 2019 Oct 7. Pharmacotherapy. 2019. PMID: 31514247 Review.
-
Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?Ther Adv Psychopharmacol. 2020 Nov 9;10:2045125320968658. doi: 10.1177/2045125320968658. eCollection 2020. Ther Adv Psychopharmacol. 2020. PMID: 33224470 Free PMC article. Review.
-
Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.J Affect Disord. 2023 Jan 1;320:353-359. doi: 10.1016/j.jad.2022.09.143. Epub 2022 Sep 30. J Affect Disord. 2023. PMID: 36191643 Clinical Trial.
-
Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.Ann Pharmacother. 2020 Feb;54(2):157-163. doi: 10.1177/1060028019873320. Epub 2019 Sep 3. Ann Pharmacother. 2020. PMID: 31476884 Review.
References
-
- Zimmerman HJ. Antidepressants. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 493-8.(Expert review of hepatotoxicity published in 1999, before the availability of brexanolone).
-
- Larrey D. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd ed. New York: Informa Healthcare USA, 2007, pp. 507-26.(Review of hepatotoxicity of antidepressants published in 2007 before the availability of brexanolone).
-
- O’Donnell JM, Bies RR, Shelton RC. Drug therapy of depression and anxiety disorders. In, Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 267-78.(Textbook of pharmacology and therapeutics).
-
- https://www.accessdata.fda.gov/scripts/cder/daf/ [ (FDA Drug Approvals website that has product labels [package inserts], letters of approval and full FDA scientific review of the new drug application for safety and efficacy). ]
-
- Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404-15. (Review of the frequency and clinical features of drug induced liver injury due to antidepressants; several SSRIs are discussed [sertraline, paroxetine, fluoxetine, citalopram, fluvoxamine], but not brexanolone). - PubMed
Publication types
LinkOut - more resources
Full Text Sources